Cantargia completes toxicity study for IL1RAP-binding antibody CAN-10

Jan. 16, 2023

Cantargia AB has completed a GLP toxicity study for its anti-inflammatory IL1RAP-binding antibody CAN-10, showing that CAN-10 was well tolerated when administered over 6 weeks.

BioWorld Science Inflammatory Antibody

Today's news in brief

BioWorld

BioWorld briefs for Oct. 14, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for October 14, 2024.

Visualization of protein folding process

Protein design: if you can’t find ’em, make ’em

BioWorld

David Baker, director of the Institute for Protein Design at the University of Washington School of Medicine, is a pioneer in protein design. His contributions...

Gilead ends $785M Yuhan deal for small-molecule MASH drugs

BioWorld

Gilead Sciences Inc. terminated a potential $785 million licensing deal with Yuhan Corp. inked in 2019 to develop metabolic dysfunction-associated steatohepatitis...

FDA gives early nod to Genentech’s first-line breast cancer drug

BioWorld

Genentech Inc. didn’t need to wait until Thanksgiving for the U.S. FDA to make up its mind. More than a month ahead of its PDUFA date, the agency approved the...

Upgrade your daily dose of biopharma and medtech news

Cantargia completes toxicity study for IL1RAP-binding antibody CAN-10